What sets research-led cannabis developers apart?
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchIndustryCBDTHCSafetyPolicyNeurology Clinical Summary # Summary Research-led cannabis developers like Oxford…
When sleep becomes the hardest part of managing a chronic condition – leafie
✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. SleepPainAnxietyNeurologyResearchSafetyPolicy Why This Matters Clinicians managing chronic pain or other conditions…
Policy Watch: 20 Regulatory Updates — June 22, 2026
This update covers DEA synthetic opioids schedule I placement actions affecting clinical and regulatory landscapes in 2026. These changes influence substance classification and patient care considerations. Stay informed on the latest controlled…
Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products
The DEA rescheduling Schedule III cannabis marks a pivotal regulatory change for FDA approved cannabis products. This shift facilitates improved medical cannabis access under federal law. Clinicians and patients should understand the implications of this…
DEA Update on Scheduling Synthetic Cannabinoids in Schedule I
The DEA scheduling synthetic cannabinoids update highlights the placement of four novel compounds into Schedule I. These synthetic cannabinoids pose significant public health risks due to their high potency and unknown safety profiles. Clinicians should…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has issued the cumyl-pegaclone schedule i designation, reflecting its high abuse potential and lack of accepted medical use. This designation highlights regulatory efforts to control synthetic cannabinoids. Clinicians should be aware of the risks…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has issued temporary scheduling orders placing 2-fluorodeschloroketamine into Schedule I. These orders address emerging synthetic drugs and their regulatory challenges. Temporary scheduling orders are critical for managing novel substances with…
Schedules of Controlled Substances: Diphenidine Scheduling Update
The DEA has updated the diphenidine controlled substance scheduling to reflect its placement in Schedule I. This change addresses the drug's high abuse potential and lack of accepted medical use. Clinicians should stay informed about diphenidine…
CED Cannabis Science Digest: Immune Activation and CB1-Target Insights
This digest highlights immune activation cannabis research focusing on HIV-linked inflammatory signaling, CB1-target drug design hurdles, and preclinical CBD brain delivery. These three verified cannabis science signals clarify current evidence limits…
Is the US Hemp Ban Punishing the Wrong People?
✦ New CED Clinical Relevance #47 Clinical Context Background information relevant to the evolving cannabis medicine landscape. HempCBDPolicySafetyIndustryResearchAnxiety Clinical Summary # Clinical Summary The article examines how US hemp…